Wire · operational-macro
Rafael's Trappsol Cyclo Misses Primary Endpoint, Targets 2026 FDA Filing
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 4 October 2026 · Fusion42 review
Rafael's Trappsol Cyclo missed the primary endpoint in its Phase III trial for Niemann-Pick Disease Type C but showed positive subgroup results and survival benefits, targeting a 2026 FDA New Drug Application filing.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You face a late-stage regulatory hurdle with Trappsol Cyclo's missed primary endpoint but positive subgroup and survival signals give a pathway to FDA filing in 2026. Prepare your clinical and commercial strategy for a complex FDA review that could reward survival benefit over primary endpoint.
◆ Coverage
1 source · 4 Oct 2026
◆ Related on Wire
◆ Topics